Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T20:14:53.218Z Has data issue: false hasContentIssue false

Community treatment orders and antipsychotic long-acting injections

Published online by Cambridge University Press:  02 January 2018

Tim J. Lambert
Affiliation:
Discipline of Psychological Medicine, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales
Bruce S. Singh
Affiliation:
Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia
Maxine X. Patel*
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, King's College London, UK
*
Dr Maxine Patel, Division of Psychological Medicine, Box 68, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK. Email: m.patel@iop.kcl.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Background

The community treatment order (CTO) is the legal framework by which people in the community are compelled to accept treatment. Both antipsychotic long-acting injections (LAIs) and CTOs are used to address treatment non-adherence.

Aims

To investigate the relationship between CTOs and LAI use in patients with schizophrenia.

Method

Prescribing, demographic and CTO data were collected for patients from four community mental health clinics in Melbourne, Australia, in 1998 and 2002.

Results

Against a background of increasing use of oral second-generation antipsychotic (SGA) medication and decreasing use of LAIs, the rates of CTO implementation doubled from 13% to 26% of patients with schizophrenia between 1998 and 2002. Proportionally more patients with a CTO are prescribed LAIs rather than oral SGAs.

Conclusions

The relationship between receiving an LAI and being subject to a CTO is significant, and reflects the consideration given to enhancing adherence in a community mental health setting.

Figure 0

Table 1Demographic details of the sample at time 1

Figure 1

Fig. 1Proportion of patients with schizophrenia according to community treatment order (CTO) status and antipsychotic formulation (FGA, first-generation antipsychotic).

Figure 2

Table 2Community treatment order status and use of long-acting injections: 1998 to 2002

Figure 3

Table 3Community treatment order status and use of oral second-generation antipsychotics: 1998 to 2002

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.